Addyi (Flibanserin) Safety in Adolescents (12 to 17): What Clinicians and Parents Should Know

FDA Approval Status and Age Restrictions

Flibanserin received FDA approval in August 2015 for a single, narrowly defined indication: acquired, generalized HSDD in premenopausal women [1]. The approval did not include any pediatric or adolescent population. The FDA label explicitly states that safety and effectiveness have not been established in patients under age 18 [2].

Why the Label Excludes Adolescents

The three registration trials that supported approval (DAISY, VIOLET, and BEGONIA) enrolled women aged 18 and older. BEGONIA (N=1,087) randomized premenopausal women to flibanserin 100 mg or placebo at bedtime for 24 weeks and reported a statistically significant but modest increase in satisfying sexual events (SSEs) of approximately 0.8 events per month over placebo [3]. No adolescent sub-study was conducted alongside these adult trials, and Sprout Pharmaceuticals has not filed any pediatric study plan with the FDA for this indication.

No Pediatric Study Requirement Was Imposed

Under the Pediatric Research Equity Act (PREA), the FDA can require manufacturers to conduct pediatric studies for drugs with potential pediatric use. For flibanserin, the FDA granted a full waiver of pediatric study requirements because HSDD, as currently defined, is not a recognized diagnosis in patients under 18 [2]. This waiver means there is no regulatory pathway actively generating adolescent safety data for this drug.

Why HSDD Is Not Diagnosed in Adolescents

HSDD requires persistent distress about low sexual desire that is not better explained by another condition, medication, or relationship factor. The DSM-5 replaced HSDD with female sexual interest/arousal disorder (FSIAD) in 2013, but even under the older DSM-IV-TR definition, the diagnosis applied to adults [4].

Developmental Context Matters

Sexual desire in adolescents is inherently variable. Pubertal timing, hormonal fluctuations, psychosocial development, and relationship experience all shape the trajectory of sexual interest during ages 12 to 17. The International Society for the Study of Women's Sexual Health (ISSWSH) and the North American Menopause Society (NAMS) have published guidance on HSDD management exclusively for adult women, with no extension to adolescent populations [5].

Distinguishing Normal Variation from Disorder

A 14-year-old reporting low sexual interest is not exhibiting pathology. Diagnosing a desire disorder requires a stable baseline of prior functioning, which most adolescents have not yet established. No validated screening tool for HSDD has been normed for patients under 18. Applying adult diagnostic criteria to adolescents risks medicalizing normal developmental variation.

Pharmacology and the Adolescent Brain

Flibanserin is a post-synaptic 5-HT1A receptor agonist and 5-HT2A receptor antagonist. It also has weak dopamine D4 receptor agonist activity. The drug modulates serotonin and dopamine signaling in the prefrontal cortex, a brain region that does not reach full structural maturity until the mid-20s [6].

Serotonin System Maturation

The serotonergic system undergoes significant remodeling during adolescence. 5-HT1A receptor density, serotonin transporter expression, and downstream signaling cascades are all in flux between ages 12 and 17 [7]. Introducing a drug that directly agonizes 5-HT1A receptors and antagonizes 5-HT2A receptors into this developing system carries theoretical risks that have never been characterized in any preclinical adolescent model or clinical study.

Parallels with Other CNS-Active Drugs

The FDA has required boxed warnings for SSRIs and SNRIs in patients under 25 because of increased suicidality risk during early treatment [8]. Flibanserin acts on some of the same neurotransmitter systems. While flibanserin is not an antidepressant and its mechanism differs from SSRIs, the principle of heightened CNS vulnerability during adolescence applies broadly. No suicidality monitoring data exists for flibanserin in any age group under 18.

Known Adult Safety Signals Relevant to Adolescent Risk

The adult safety profile of flibanserin, established across the BEGONIA, DAISY, and VIOLET trials (combined N of approximately 3,000 women on flibanserin), includes several adverse effects that carry amplified concern in younger patients [3][9].

Hypotension and Syncope

Flibanserin carries a Risk Evaluation and Mitigation Strategy (REMS) program specifically because of the risk of severe hypotension and syncope when combined with alcohol or moderate-to-strong CYP3A4 inhibitors [2]. Adolescents may be less likely to disclose alcohol use to prescribers, making this interaction harder to monitor. Blood pressure in adolescents is also more labile than in adults, and orthostatic hypotension can cause falls, concussions, and injury during physical activity.

CNS Depression and Sedation

The most common adverse reactions in adult trials were dizziness (11.4% vs. 2.2% placebo), somnolence (11.2% vs. 3.1% placebo), and fatigue (9.2% vs. 5.5% placebo) [2]. For adolescents attending school, participating in sports, driving (ages 16 to 17), or operating machinery, these effects present functional and safety risks that differ qualitatively from those faced by adult patients.

Drug-Drug Interaction Burden

Flibanserin is extensively metabolized by CYP3A4, CYP2C19, and CYP1A2 [2]. Adolescents taking combined oral contraceptives (which inhibit CYP3A4), acne medications, or psychotropic drugs for ADHD or anxiety face a complex interaction field. No pharmacokinetic studies have evaluated flibanserin drug interactions in patients under 18.

What the Professional Guidelines Say

No major medical society recommends flibanserin for adolescents. The ISSWSH 2022 process of care algorithm for HSDD management specifies the population as "adult premenopausal women" [5]. The American College of Obstetricians and Gynecologists (ACOG) Committee Opinion on female sexual dysfunction does not address pediatric or adolescent use of any pharmacotherapy for desire disorders [10].

The Endocrine Society Position

The Endocrine Society's clinical practice guideline on testosterone therapy in women (2019) explicitly excludes adolescents from recommendations for pharmacologic management of low desire, noting insufficient evidence in this age group [11]. While that guideline addresses testosterone rather than flibanserin, the exclusion reflects a broader consensus: pharmacologic treatment of desire complaints in adolescents lacks an evidence base.

Off-Label Prescribing Considerations

Physicians retain the legal authority to prescribe FDA-approved drugs off-label, including to patients outside the approved age range. Off-label use requires that the prescriber judge the potential benefit to outweigh the risk based on available evidence. For flibanserin in adolescents, no evidence of benefit exists, while theoretical risks from CNS effects on the developing brain are substantive. The risk-benefit calculus does not support off-label adolescent use under current data.

Comparative Context: How Other CNS Drugs Handle Adolescent Populations

Understanding how regulatory agencies and manufacturers have approached adolescent safety for other CNS-active medications helps contextualize the flibanserin evidence gap.

SSRIs Required Dedicated Pediatric Trials

Fluoxetine is the only SSRI with full FDA approval for adolescent major depressive disorder, and that approval required the Treatment for Adolescents with Depression Study (TADS, N=439) demonstrating efficacy and acceptable safety in patients aged 12 to 17 [12]. The TADS trial also identified the elevated suicidality signal that led to the class-wide boxed warning. This example illustrates that adult safety data cannot be extrapolated to adolescents without dedicated studies, even for drugs with established mechanisms.

Modafinil Pediatric Development Was Halted

Cephalon pursued a pediatric indication for modafinil for ADHD but halted development after a pediatric trial revealed a serious dermatologic adverse event (Stevens-Johnson syndrome) that had not been observed at the same rate in adult populations [13]. This case demonstrates that adolescents can exhibit novel adverse effects not predicted by adult trial data.

If an Adolescent Reports Low Sexual Desire

When an adolescent patient or their parent raises concerns about sexual desire, the clinical response should focus on assessment rather than pharmacotherapy.

Recommended Evaluation Steps

Screen for depression, anxiety, and trauma history, which are common drivers of low desire at any age. Review current medications, since SSRIs, hormonal contraceptives, and anti-seizure drugs can all suppress desire as a side effect. Evaluate endocrine function if clinically indicated (thyroid panel, prolactin). Assess relationship dynamics and psychosocial stressors through age-appropriate counseling.

When to Refer

Adolescents with persistent distress about sexual function should be referred to a mental health provider with training in adolescent sexuality. The Society for Adolescent Health and Medicine (SAHM) maintains referral resources. Cognitive-behavioral therapy (CBT) and psychoeducation about normal sexual development are first-line interventions for desire-related distress in young patients [14].

Monitoring Considerations If Off-Label Use Occurs

Despite the absence of evidence supporting this practice, if a clinician prescribes flibanserin off-label to a patient aged 16 to 17, the following monitoring framework should be considered based on the known adult adverse-effect profile and adolescent-specific vulnerabilities.

Baseline and Ongoing Assessments

Obtain baseline orthostatic vital signs before starting therapy. Screen for alcohol use at every visit using a validated adolescent tool such as the CRAFFT questionnaire. Assess mood and suicidality using the PHQ-A (Patient Health Questionnaire for Adolescents) at baseline, 4 weeks, 8 weeks, and quarterly thereafter. Document informed consent from both the patient and a legal guardian, including explicit discussion that this use is not FDA-approved and no pediatric safety data exists.

Drug Interaction Screening

Review the full medication list for CYP3A4 inhibitors (fluconazole, erythromycin, combined oral contraceptives), CYP2C19 substrates, and any CNS depressants. Flibanserin is contraindicated with moderate or strong CYP3A4 inhibitors [2]. Grapefruit juice, which many adolescents consume, also inhibits CYP3A4 and should be avoided.

Discontinuation Criteria

Stop flibanserin immediately if the patient reports syncope, pre-syncope, or any fall. Discontinue if there is no perceived benefit after 8 weeks of consistent bedtime dosing, consistent with the adult recommendation [2]. Reassess the diagnosis if discontinuation reveals no change in desire, as this may indicate the original complaint was within normal developmental range.

The Evidence Gap: What Research Would Be Needed

Generating adolescent safety data for flibanserin would require a structured program that no sponsor has initiated or is likely to pursue, given the PREA waiver and the narrow commercial indication.

Minimum Study Requirements

A Phase 1 pharmacokinetic study in adolescents aged 16 to 17 to characterize dose-exposure relationships, given differences in hepatic metabolism, body composition, and protein binding between adolescents and adults. A Phase 2 safety and tolerability study with prospective neurocognitive testing and mood monitoring over at least 24 weeks. Development and validation of an adolescent-specific outcome measure for sexual desire, since existing HSDD instruments (FSDS-R, FSFI) were designed for and validated in adult women only.

Why This Research Likely Will Not Happen

The commercial incentive is minimal. Flibanserin's adult market performance has been modest since launch, with Sprout Pharmaceuticals reporting limited uptake relative to initial projections. The PREA waiver removes regulatory pressure. And the ethical barriers to enrolling minors in a sexual desire drug trial are substantial, requiring institutional review board approval that many ethics committees would be reluctant to grant absent a clear unmet medical need in this age group.

Key Takeaway for Prescribers and Families

Flibanserin has zero published safety or efficacy data in patients aged 12 to 17. No clinical trial has enrolled an adolescent participant. No guideline endorses its use in this age group. The drug's CNS mechanism (5-HT1A agonism, 5-HT2A antagonism) interacts with neurotransmitter systems that are actively remodeling during adolescence, and the REMS-level risks of hypotension and syncope carry amplified consequences for young, physically active patients. Any adolescent presenting with concerns about sexual desire should receive a thorough psychosocial and medical evaluation, with referral to an adolescent mental health specialist as the appropriate first step, not a prescription for flibanserin. The FDA-approved adult dose is 100 mg nightly, and there is no established pediatric dose for any age.